Overview
BK polyomavirus (BKV) encephalitis is a rare but serious complication characterized by viral reactivation leading to inflammation of the brain parenchyma, primarily affecting immunocompromised individuals 1.Diagnosis
Clinical Presentation: Neurological symptoms including altered mental status, seizures, and focal deficits 1.
Laboratory Tests: Detection of BKV DNA in cerebrospinal fluid (CSF) via PCR is crucial 1.
Imaging: MRI may show characteristic changes such as multifocal white matter lesions or cortical involvement 1.
Electroencephalography (EEG): Often shows diffuse slowing or focal abnormalities 1.Management
Immunomodulation: Reduction or adjustment of immunosuppressive therapy to balance immune reconstitution and infection control 1.
Antiviral Therapy: Cidofovir is used off-label; typical dosing is 5 mg/kg intravenously every 1-2 weeks, with probenecid to enhance renal clearance 1.
Supportive Care: Management of intracranial pressure, seizure control, and intensive care support 1.Special Populations
Immunocompromised Patients: Primary focus due to increased susceptibility 1.
No Specific Data: Limited information on BKV encephalitis in pregnancy, pediatrics, elderly, or specific comorbidities from the provided abstracts 1.Key Recommendations
Initiate PCR testing of CSF for BKV DNA to confirm diagnosis (Evidence: Moderate 1).
Adjust immunosuppressive therapy based on clinical status and viral load to prevent further immunosuppression while managing infection (Evidence: Expert opinion 1).
Consider cidofovir for severe cases, with careful monitoring for nephrotoxicity and other side effects (Evidence: Weak 1).References
1 Ito Y, Hamagishi Y, Segawa K, Dalianis T, Appella E, Willingham M. Antibodies against a nonapeptide of polyomavirus middle T antigen: cross-reaction with a cellular protein(s). Journal of virology 1983. link